Aortic Valve DiseaseNCT00677638
Transapical Implantation of Ventor Embracer™ Valve in Patients With Severe Aortic Valve Disease
A study testing Ventor Embracer in people with Aortic Valve Disease, run by Ventor Technologies at 3 sites in Germany.
Trial summary
A prospective single arm study evaluating feasibility and safety of a catheter-based transapical implantation of the Ventor Embracer™ aortic valve bioprosthesis in patients with severe aortic valve disease, specifically aortic stenosis, who are at elevated risk for standard surgical valve replacement. Read more about this study
- Who is it for?
- Ages 75 years and older
- Conditions the study is for
- Aortic Valve Disease
- What is being tested?
- Ventor Embracer
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 3 sitesGermany
- Study dates
- Jun 2008to Dec 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Patient understands the implications of participating in the study and provides informed consent
- Patient is willing to comply with specified follow-up evaluation and can be contacted by telephone
- Age >75 years
- Severe, aortic stenosis (echocardiographically derived mean gradient > 40 mm Hg, and/or jet velocity > 4m/s, or an initial aortic valve area of < 0.8 cm2)
- Symptoms related to the aortic valve disease, as demonstrated by NYHA Functional Class II or greater
- EuroSCORE scale of >9 points indicating a predicted risk for mortality of >11% according to the logistic EuroSCORE
- Echocardiographically determined anteroposterior aortic annulus diameter of >19 and <23 mm
- Echocardiographically determined sinotubular junction diameter of ≥23 mm
Who cannot join
- Congenital unicuspid or bicuspid aortic valve
- Fused commissures
- Severe eccentricity of calcification
- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
- Severe left ventricular dysfunction (LVEF < 25%)
- More than mild right ventricular dysfunction
Show all 29Show fewer
- Hypertrophic obstructive cardiomyopathy
- Moribund patients, or patients with a noncardiac disease limiting by itself life expectancy to less than 12 months
- Known hypersensitivity or contraindication to any study medication
- Known sensitivity to contrast medium that cannot be adequately controlled with pre-medication
- Known allergy or sensitivity to Nitinol
- Sepsis, or acute endocarditis
- Blood dyscrasia such as acute anemia, leucopenia, or thrombocytopenia; bleeding diathesis, or coagulopathy.
- Renal insufficiency and/or end stage renal disease requiring chronic dialysis
- Liver disease as indicated by jaundice, ascites, ALT/AST > 3 x ULN, elevation of total bilirubin > 1.5 mg/dl, albumin < 3.0 g/l, or INR > 1.5 (if not on anticoagulation).
- Significant lung disease (e.g. FEV1 < 1.2L or FEV1 < 50%).
- Active peptic ulcer or GI bleeding within 3 months from the planned index procedure
- Untreated clinically significant coronary artery disease requiring revascularisation
- Cardiogenic shock, suspected cardiogenic shock, or hemodynamic instability requiring inotropic support or mechanical heart assistance
- Peripheral vascular disease, including abdominal and thoracic aortic disease, which could pose a problem for eventual transarterial mechanical support (e.g. Intraaortic Balloon Pump)
- Need for emergency surgery, cardiac or noncardiac
- History of myocardial infarction in the last 6 weeks.
- History of TIA or stroke in the last 6 months.
- Any therapeutic invasive cardiac procedure, except aortic balloon valvuloplasty, performed within 30 days from the planned index procedure, or 6 months, in case of implantation of drug-eluting stents.
- Uncontrolled atrial fibrillation
- Pre-existing aortic valve replacement
- Severe (greater than 3+) mitral regurgitation
- Severe (greater than 3+) aortic regurgitation
- Patient is currently enrolled in another investigational device or drug trial
Trial locations and contacts
3 sites in 1 country.
Germany3 sites
Prof. Thorsten Wahlers
Cologne, 50924
Prof. Jochen Schaefers
Homburg, 66421
Friedrich Mohr, MD
Leipzig, 04289
About this study
Official title: Catheter-Based Transapical Implantation of the Ventor Embracer™ Heart Valve Prosthesis in Patients With Severe Aortic Valve Disease
A prospective single arm study evaluating feasibility and safety of a catheter-based transapical implantation of the Ventor Embracer™ aortic valve bioprosthesis in patients with severe aortic valve disease, specifically aortic stenosis, who are at elevated risk for standard surgical valve replacement.
- Conditions
- Aortic Valve Disease
- Being tested
- Ventor Embracer
- Medical subject headings
- Aortic Valve Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ventor EmbracerDevice
Implantation of Ventor Embracer
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Embracer implantation Receives: Device: Ventor Embracer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Stable device placement and adequate function as assessed by angiography and echocardiography immediately post-procedure
Measured: day one
A composite of any death, myocardial infarction, or disabling stroke at 30 days post-procedure
Measured: 30 days
Secondary outcomes (6)
Device success and the absence of periprocedural MACCEs at post-operative day 1
Measured: day one
Any of the following adverse events: death, myocardial infarction, disabling stroke, repeat aortic valve procedure, cardiogenic shock, or endocarditis at 30 days
Measured: 30 days
Any of the following adverse events: death, disabling stroke, repeat aortic valve procedure or endocarditis at 6 months
Measured: 6 months
Freedom from death at 1 year
Measured: 1 year
Functional improvement from baseline per New York Heart Association (NYHA) functional classification at 30 days, 6 months and 1 year
Measured: 1 year
Peak & mean pressure gradient, derived calculated measures of prosthetic valve function, aortic regurgitation - assessed by echocardiography immediately after deployment, at POD 1, 30 days, 6 months and 5 years annually
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2008 (estimated)
- Study startJun 2008
- Primary completionJan 2010 (estimated)
- Study completionDec 2014 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Aortic Valve DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ventor Technologies
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Jochen Schaefers, MD, Principal investigator, Universitatsklinikum des SaarlandesFriedrich Mohr, MD, Principal investigator, Universität Leipzig
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00677638
- Sponsor's protocol ID
- CLIN004
- Status last verified
- Dec 2009
- First submitted
- 12 May 2008
- Last updated
- 3 Dec 2009
- Results posted
- No
- Data monitoring committee
- No
Publications
Falk V, Walther T, Schwammenthal E, Strauch J, Aicher D, Wahlers T, Schafers J, Linke A, Mohr FW. Transapical aortic valve implantation with a self-expanding anatomically oriented valve. Eur Heart J. 2011 Apr;32(7):878-87. doi: 10.1093/eurheartj/ehq445. Epub 2010 Dec 9.
PubMed 21148541
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Catheter-Based Transapical Implantation of the Ventor Embracer™ Heart Valve Prosthesis in Patients With Severe Aortic Valve Disease
- ClinicalTrials.gov ID
- NCT00677638
- Acronym / sponsor ID
- CLIN004
- Conditions
- Aortic Valve Disease
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Ventor TechnologiesIndustry (pharma, biotech, devices)
- Study start
- Jun 2008
- Primary completion
- Jan 2010 (estimated)
- Study completion
- Dec 2014 (estimated)
- First posted
- 14 May 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A prospective single arm study evaluating feasibility and safety of a catheter-based transapical implantation of the Ventor Embracer™ aortic valve bioprosthesis in patients with severe aortic valve disease, specifically aortic stenosis, who are at elevated risk for standard surgical valve replacement.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Device: Ventor EmbracerEmbracer implantation |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (8 listed)
- Patient understands the implications of participating in the study and provides informed consent
- Patient is willing to comply with specified follow-up evaluation and can be contacted by telephone
- Age >75 years
- Severe, aortic stenosis (echocardiographically derived mean gradient > 40 mm Hg, and/or jet velocity > 4m/s, or an initial aortic valve area of < 0.8 cm2)
- Symptoms related to the aortic valve disease, as demonstrated by NYHA Functional Class II or greater
Key exclusion criteria (29 listed)
- Congenital unicuspid or bicuspid aortic valve
- Fused commissures
- Severe eccentricity of calcification
- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
- Severe left ventricular dysfunction (LVEF < 25%)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ventor EmbracerImplantation of Ventor Embracer | Device | 1 |
Primary outcome
Stable device placement and adequate function as assessed by angiography and echocardiography immediately post-procedure
Time frame: day one
A composite of any death, myocardial infarction, or disabling stroke at 30 days post-procedure
Time frame: 30 days
6 secondary outcomes
Device success and the absence of periprocedural MACCEs at post-operative day 1
Time frame: day one
Any of the following adverse events: death, myocardial infarction, disabling stroke, repeat aortic valve procedure, cardiogenic shock, or endocarditis at 30 days
Time frame: 30 days
Any of the following adverse events: death, disabling stroke, repeat aortic valve procedure or endocarditis at 6 months
Time frame: 6 months
Freedom from death at 1 year
Time frame: 1 year
Functional improvement from baseline per New York Heart Association (NYHA) functional classification at 30 days, 6 months and 1 year
Time frame: 1 year
Peak & mean pressure gradient, derived calculated measures of prosthetic valve function, aortic regurgitation - assessed by echocardiography immediately after deployment, at POD 1, 30 days, 6 months and 5 years annually
Time frame: 5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2009.
- Derived from this study: PubMed 21148541Falk V, Walther T, Schwammenthal E, Strauch J, Aicher D, Wahlers T, Schafers J, Linke A, Mohr FW. Transapical aortic valve implantation with a self-expanding anatomically oriented valve. Eur Heart J. 2011 Apr;32(7):878-87. doi: 10.1093/eurheartj/ehq445. Epub 2010 Dec 9.
Related trials for Aortic Valve Disease
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Recruiting
Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI Trial
Aortic Stenosis Disease, Aortic Stenosis Symptomatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jochen Schaefers, MD principal investigator
Universitatsklinikum des Saarlandes
Friedrich Mohr, MD principal investigator
Universität Leipzig
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ventor Embracer in people with Aortic Valve Disease, run by Ventor Technologies at 3 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Dec 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Stable device placement and adequate function as assessed by angiography and echocardiography immediately post-procedure (time frame: day one). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00677638, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2009.